What Is the Tirzepatide Compound?
Tirzepatide is a synthetic peptide compound developed by Eli Lilly. It’s a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, making it a unique innovation in the treatment of type 2 diabetes and obesity.
Dual Incretin Mechanism
What sets Tirzepatide apart is its dual-action mechanism. It activates both GIP and GLP-1 receptors, which helps regulate insulin secretion, decrease glucagon levels, and slow gastric emptying. This results in better blood sugar control and reduced appetite.
Tirzepatide is compounded in labs for research or pharmacy-specific use, but FDA-approved versions are available under brand names like Mounjaro. While compounded Tirzepatide may offer cost savings, it’s crucial to use pharmacy-grade sources to ensure quality, safety, and efficacy.
Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or adjusting any medication.
